Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Short- and long-term outlook after emergency admission for acute heart failure

Official title: Short and Long Term Prognosis of Patients Admitted to the Emergency Department With Acute Heart Failure

Run by University of Monastir · NCT03806972 · Data updated 2026-11-12

This project will try to see how people admitted to the emergency department with acute heart failure do at 30 days and one year, comparing those with reduced versus preserved ejection fraction.

More Acute Heart Failure trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment3000 (estimated)
SponsorUniversity of Monastir
Academic / other
Locations1 site (Monastir, Monastir Governorate)
StatusRecruiting
StartedJune 1, 2009
Main results expectedDecember 1, 2030
Study endsDecember 1, 2030
Registry record updatedJuly 22, 2025
Trial IDNCT03806972 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults admitted to the Emergency Department at the University of Monastir with a primary discharge diagnosis of acute heart failure who can consent and comply with follow-up.

Probably not a fit

Patients who are pregnant or breastfeeding, those with altered consciousness or requiring immediate mechanical or ventilatory support, or those unable to comply with follow-up are excluded and unlikely to benefit from this observational work.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort of adults admitted to the Emergency Department at the University of Monastir with a primary discharge diagnosis of acute heart failure. Patients will be classified as heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) and baseline clinical data will be recorded. The main outcomes are mortality and rehospitalization at 30 days and one year, determined through clinic follow-up and medical record review. Pregnant or breastfeeding patients, those with altered consciousness or needing immediate mechanical/hemodynamic/ventilatory support, and individuals unable to comply with follow-up are excluded and no interventional treatments are assigned.

Why it matters

Potential benefit: If successful, the results could help clinicians predict which emergency-admitted heart failure patients are at higher short- and long-term risk and improve follow-up and care planning.

How similar studies have gone: Many prior observational studies have compared outcomes between HFrEF and HFpEF, so this project builds on an established evidence base rather than introducing a novel treatment.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients admitted to the ED of Monastir with a principal discharge diagnosis code for HF.

Exclusion Criteria:

* Pregnant or breast feeding women. Alteration of consciousness GCS \< 15 Critically ill patients needing immediate mechanical hemodynamic of ventilatory support.

Inability to follow instructions or comply with follow-up procedures.

Where it's running

  • Emergency Departement
    Monastir, Monastir Governorate, Tunisia
    Recruiting

Study contacts

  • Principal investigator: Nouira Semir, Professor — university Hospital of Monastir
  • Study coordinator: Nouira Semir, Professor
  • Email: semir.nouira@rns.tn
  • Phone: 73106000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.